Clinical experience with the use of peripheral vasodilator in oral disorders

Sharma, Jaydev; Gupta, Ayushman; Mukhija, R. D.; Nigam, P

doi:10.1016/s0901-5027(87)80055-3

Cited by 30 publications

(21 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increase in the chewing habit of the areca nut without any tobacco and the use of various commercial products containing areca nut may explain the decrease in the age of OSMF cases due to various chewing habits. [15][16][17][18][19][20] The mean age of occurrence was lower in males than in females and the difference was statistically significant (P < 0.001).…”

Section: Discussionmentioning

confidence: 99%

A comparative study on efficacy of different treatment modalities of oral submucous fibrosis evaluated by clinical staging in population of Southern Rajasthan

Goel¹,

Ahmed²

2015

J Can Res Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A comparative study on efficacy of different treatment modalities of oral submucous fibrosis evaluated by clinical staging in population of Southern Rajasthan

Goel¹,

Ahmed²

2015

J Can Res Ther

View full text Add to dashboard Cite

show abstract

“…β‐adrenergic agonist drugs (nylidrin hydrochloride) such as xamotorol produce arteriolar vasodilatation in skeletal muscles and are considered to have direct vasodilatory effect on vascular smooth muscle. These agents have been shown to reverse mucosal suppleness in OSMF after use …”

Section: Medical Treatmentsmentioning

confidence: 99%

Current protocols in the management of oral submucous fibrosis: An update

Arakeri

Kumar

Boraks³

et al. 2017

J Oral Pathology Medicine

View full text Add to dashboard Cite

Oral submucous fibrosis (OSMF) is a debilitating condition of oral cavity which has significant potential for malignant transformation. In spite of over 20 years of research, the pathogenesis of the condition is still obscure and no single management modality is effective. Many OSMF treatment protocols have been proposed to alleviate the signs and symptoms of the disorder and there is overwhelming evidence that as areca nut is primary cause, stopping its use may have a considerable effect on symptoms rather than reversing pre-existing fibrosis. We present a review of the current protocols for managing OSMF.

show abstract

“…[17] Nylidrin hydrochloride a peripheral vasodilator affects the tissues in diffuse fibrosis to a noticeable degree by relieving the local ischemic effect and also helps the nutritional and therapeutic substances to reach the affected tissues, because it has been observed that oral submucous fibrosis symptoms include local ischemic effects secondary to local fibrous conditions, hyperkeratosis, and loss of suppleness . [20] …”

Section: Peripheral Vasodilatorsmentioning

confidence: 99%

“…[16] Combined therapy with nylidrin hydrochloride , vitamins D, E and B complex, iodine, placental extract, local and systemic corticosteroids, and physiotherapy claims a success rate of 62% in OSF. [20] …”

Section: Combination Therapymentioning

confidence: 99%